Loading
Treatment of Major Depression · Journal article
Indian Journal of Medical Specialities · July 20, 2026
A consensus or society position rather than new primary data.
This narrative review examines depression as a comorbidity in schizophrenia, documenting its high prevalence, underrecognition, and clinical impact on outcomes including relapse and suicide risk. It synthesizes current evidence on pharmacological and psychosocial management approaches and identifies precision psychiatry, biomarkers, and neurostimulation as emerging directions, while calling for improved diagnostic frameworks and longitudinal research.
Narrative review. Individuals with schizophrenia and comorbid depression..
Depression is a frequent and clinically significant comorbidity in schizophrenia, contributing to poorer functional outcomes, reduced quality of life, increased relapse rates, and elevated suicide risk. Depressive symptomatology in schizophrenia remains underrecognized and undertreated due to diagnostic overlap with negative symptoms, demoralization, and medication-related effects. Integrated management strategies include pharmacological optimization, adjunctive antidepressants, psychosocial and psychological interventions, and multidisciplinary recovery-oriented care models.
Integrated management strategies include pharmacological optimization, adjunctive antidepressants, psychosocial and psychological interventions, and multidisciplinary recovery-oriented care models.
This review highlights depression in schizophrenia as a clinically significant and undertreated comorbidity. Clinicians should consider integrated approaches combining pharmacological, psychosocial, and recovery-oriented strategies, while recognizing diagnostic challenges and evaluating emerging precision psychiatry methods.
This is a narrative review synthesizing evidence on epidemiology, mechanisms, and management strategies for depression in schizophrenia, providing clinical guidance rather than reporting original empirical findings.
As stated by the source record.
This review highlights depression in schizophrenia as a clinically significant and undertreated comorbidity. Clinicians should consider integrated approaches combining pharmacological, psychosocial, and recovery-oriented strategies, while recognizing diagnostic challenges and evaluating emerging precision psychiatry methods.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Depression is a frequent and clinically significant comorbidity in schizophrenia, contributing to poorer functional outcomes, reduced quality of life, increased relapse rates, and elevated suicide risk. Despite its substantial impact, depressive symptomatology in schizophrenia remains underrecognized and undertreated due to diagnostic overlap with negative symptoms, demoralization, and medication-related effects. This narrative review examines the epidemiology, phenomenology, and underlying neurobiological and psychosocial mechanisms of depression in schizophrenia, with a particular focus on integrated management strategies. Current evidence on pharmacological optimization, adjunctive antidepressant use, and psychosocial and psychological interventions is discussed alongside multidisciplinary and recovery-oriented care models. Emerging paradigms, including precision psychiatry, biomarker-guided approaches, neurostimulation techniques, and lifestyle-based interventions, are highlighted as promising directions for future care. The review underscores the need for longitudinal research, refined diagnostic frameworks, and context-sensitive implementation strategies to advance holistic, patient-centered management of depression in schizophrenia.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.